about
Treating refractory leukemias in childhood, role of clofarabineExpression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemiaOral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemiaCD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhoYoung adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's OnConstitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).Improving access to novel agents for childhood leukemia.Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic lFeasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupOutcomes after induction failure in childhood acute lymphoblastic leukemia.Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia.Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trialThe role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.Childhood acute lymphoblastic leukaemia and relapse.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment StrategiesEarly postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupA retrieval system for a library of pathology reports, slides and kodachromes.A computer-based system for management of clinical and laboratory data of a comprehensive sickle cell center.Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesNanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemiaPhase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]
P50
Q24647279-C56CE40B-D2F2-429A-B790-199FC67F2874Q28138910-7C721BBD-2AD7-489F-AEF3-6D2A4A8C34AAQ33388076-070B83A1-1A72-41E8-A367-0DE9A3119E19Q33628794-C1AADD06-0475-4261-AA05-4EE3080A4A49Q33740366-F68F8C7F-5399-40FA-BE09-C59055D9FD00Q33801811-B17CD9CE-A56A-4FBC-AE51-041CFDE0D8D6Q33857860-942635C6-F418-4044-83B3-E205DBED4DF7Q34003323-C0522EB4-62A4-4437-BB78-CDF410D1216DQ34154213-1761D867-C40B-4C43-B9D6-12AE1F9E5BD0Q34154532-7CF7D83D-718C-4874-A5BE-9B71610DCAA5Q34278437-A2697564-516B-442A-A3DA-C6ABA94A0BA2Q34547528-36906808-245B-4C7F-9D5B-41DEFB708713Q34645985-CE44DB0D-3DDC-4140-90A5-9642C9993A24Q34707213-09710588-ECE5-4939-8F80-C764DBF6DB7EQ34810036-ABEA8EF6-2406-468C-8737-25534349D4D6Q34820131-92E91F8B-83C3-4E78-9E99-34C21DDCDBC3Q35039727-5F693A3C-ACBD-4CF3-9D82-9DCEBD6CEC8FQ35053686-5EB3FC89-9D90-4792-B52B-9A0E9B249A4DQ35112206-02D4570A-C671-42AA-8687-B82C8B414ED2Q35616078-18FA4A9B-A19D-4674-B001-2EEC8873E3CEQ35688742-87962C8D-B963-4022-822F-87824C3A5A4FQ35849907-9E8A1EB4-DF9F-4D2E-A955-BC958E0EC77DQ35953635-0BD324C4-7AA3-4FDA-A193-D8C96E707898Q36029619-158F6108-2D26-414F-95A3-F4570E3DC62DQ36058255-0AF02EFC-E43D-4C62-ABDF-C2B4146B0BD2Q36093798-9612A0F9-5F04-4D10-9EEF-2FB8EB3E2FE8Q36218118-19C15167-07AD-4175-8466-4CC5CB6A3978Q36251056-68C33651-0CC0-49CF-808D-7EFAE3354CDEQ36308562-C9634C35-EE0F-4066-8AB6-8A64C1A4B280Q36340652-B2C1C334-9A1A-4914-9B20-F647936C7762Q36363377-EFD29C1D-8976-447E-9176-B947DCDFC6CBQ36469789-E40FA06D-C199-4E3B-BC3B-2C8C4D0BDEE7Q36478435-13F627C7-0B32-4182-A7B5-6A8F2D6B610AQ36503504-C9A5A605-604D-49EF-84C9-E4309044DA22Q36515241-E5D0AD8A-EF2B-4536-BBDF-E405C72E5E9DQ36697877-533C56D4-E035-4F9F-9B59-4F7424E4105EQ36843677-5DA6B81E-9190-46D7-96F8-170F9F0343F9Q36873283-73A80C3B-2A46-4DAB-9042-6F0AEEC00768Q37064875-C8E02A07-B6D5-4CF6-B591-8739DCE16562Q37124911-34E47F42-8D0F-4608-BEEE-59421B49D025
P50
name
Paul S. Gaynon
@en
type
label
Paul S. Gaynon
@en
prefLabel
Paul S. Gaynon
@en